COST-EFFECTIVENESS OF GRAZOPREVIR / ELBASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS

被引：0
|
作者：
Mattingly, T. J., III [1 ]
Slejko, J. F. [1 ]
Mullins, C. D. [1 ]
机构：
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.396
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN47
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [31] HEPATITIS C VIRUS TREATMENT WITH ELBASVIR/GRAZOPREVIR IN PATIENTS WITH RECENT OR CURRENT SUBSTANCE USE
    Martin, Michelle T.
    Burgos, Rodrigo
    Smith, Renata
    Michienzi, Sarah
    HEPATOLOGY, 2021, 74 : 593A - 593A
  • [32] THE COST-EFFECTIVENESS ANALYSIS OF ELBASVIR/GRAZOPREVIR VERSUS PEGINTERFERON ALPHA-2A IN COMBINATION WITH RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1B INFECTION IN CHINA
    Chen, P. Y.
    Liu, Q.
    Li, H. C.
    Ma, A. X.
    VALUE IN HEALTH, 2018, 21 : S65 - S65
  • [33] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C - Reply
    Myers, RP
    Gregor, JC
    Marotta, PJ
    HEPATOLOGY, 2000, 32 (04) : 874 - 875
  • [34] The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis
    Jacobs, RJ
    Koff, RS
    Meyerhoff, AS
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (02): : 427 - 434
  • [35] Effectiveness and safety of elbasvir grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
    Jang, Eun Sun
    Kim, Kyung-Ah
    Kim, Young Seok
    Kim, In Hee
    Lee, Byung Seok
    Lee, Youn Jae
    Chung, Woo Jin
    Jeong, Sook-Hyang
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 : S1 - U328
  • [36] Cost-effectiveness of elbasvir/grazoprevir (EBR/GZR) for treatment-naive (TN) patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection in Russia
    Corman, Shelby
    Puenpatom, Amy
    Kulikov, Andrey
    Yagudina, Roza
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E503 - E504
  • [37] A real-world study on the effectiveness of elbasvir/grazoprevir in the treatment of genotype 1 chronic hepatitis C
    李宽
    China Medical Abstracts(Internal Medicine), 2021, 38 (02) : 109 - 109
  • [38] US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
    Sarita D. Boyd
    LaRee Tracy
    Takashi E. Komatsu
    Patrick R. Harrington
    Prabha Viswanathan
    Jeff Murray
    Adam Sherwat
    Clinical Drug Investigation, 2017, 37 : 317 - 326
  • [39] US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
    Boyd, Sarita D.
    Tracy, LaRee
    Komatsu, Takashi E.
    Harrington, Patrick R.
    Viswanathan, Prabha
    Murray, Jeff
    Sherwat, Adam
    CLINICAL DRUG INVESTIGATION, 2017, 37 (04) : 317 - 326
  • [40] Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network
    Younossi, Z.
    Bacon, B.
    Curry, M.
    Dieterich, D.
    Flamm, S.
    Kowdley, K.
    Milligan, S.
    Nwankwo, C.
    Tsai, N.
    Afdhal, N.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S748 - S749
12345